Harvard Apparatus Reports 31% Revenue Growth in Q2 2026 Despite Operating Losses

Harvard Apparatus Regenerative Technology, Inc. reported its financial results for the second quarter of 2026, revealing a product revenue of $414,000, a 31% increase from $317,000 in the same period last year. For the first half of 2026, the company generated $640,000 in revenue, marking a 77% rise compared to $362,000 in the first half of 2025. Despite this growth in revenue, the company continues to face significant operating losses, reporting a net loss of $1.7 million for the second quarter and $3.3 million for the first half of 2026, slightly improved from losses of $1.8 million and $3.5 million, respectively, in the prior year.

The company's operating expenses for the second quarter totaled $2.1 million, a marginal decrease from $2.15 million in the same quarter of 2025. Notably, research and development expenses rose by 36% to $948,000, reflecting increased costs associated with clinical activities. Conversely, general and administrative expenses decreased by 35% to $751,000, primarily due to lower share-based compensation expenses. The company’s cost of sales also increased, aligning with the growth in product revenue, rising to $391,000 from $302,000 year-over-year.

In terms of strategic developments, Harvard Apparatus is actively pursuing its clinical trial for its esophageal implant, which has received FDA approval for a Phase 1 trial. The company has contracted with IQVIA to manage this trial, although it has faced challenges in patient recruitment due to stringent eligibility criteria and logistical issues. The company is also expanding its consumer health product offerings, which include dietary supplements marketed primarily in Asia, contributing to the revenue growth reported.

As of June 30, 2026, Harvard Apparatus had an accumulated deficit of approximately $109.9 million and total assets of $1.7 million, down from $2.7 million at the end of 2025. The company’s cash and cash equivalents decreased to $351,000 from $1.35 million, raising concerns about its liquidity. To address its financial needs, the company has secured $500,000 in convertible debt from its CEO and anticipates additional cash advances from investors, which are expected to support operations into the fourth quarter of 2026. However, the company has indicated that it will need to raise further capital to continue its operations beyond this period, highlighting ongoing financial challenges.